KR101997023B1 - Hydrangea macrophylla extract mixed composition for relaxation and reducing concentration and uses thereof - Google Patents
Hydrangea macrophylla extract mixed composition for relaxation and reducing concentration and uses thereof Download PDFInfo
- Publication number
- KR101997023B1 KR101997023B1 KR1020180151614A KR20180151614A KR101997023B1 KR 101997023 B1 KR101997023 B1 KR 101997023B1 KR 1020180151614 A KR1020180151614 A KR 1020180151614A KR 20180151614 A KR20180151614 A KR 20180151614A KR 101997023 B1 KR101997023 B1 KR 101997023B1
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- hydrangea
- extract
- concentration
- mixture
- Prior art date
Links
- 235000014486 Hydrangea macrophylla Nutrition 0.000 title claims abstract description 66
- 244000267823 Hydrangea macrophylla Species 0.000 title claims abstract description 65
- 239000000203 mixture Substances 0.000 title claims abstract description 63
- 239000000284 extract Substances 0.000 title abstract description 55
- 238000001228 spectrum Methods 0.000 claims abstract description 29
- 235000013376 functional food Nutrition 0.000 claims abstract description 8
- 230000036541 health Effects 0.000 claims abstract description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 20
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 18
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 18
- 239000000843 powder Substances 0.000 claims description 18
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 16
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 10
- 239000003086 colorant Substances 0.000 claims description 10
- 235000011187 glycerol Nutrition 0.000 claims description 10
- 239000008101 lactose Substances 0.000 claims description 10
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 claims description 9
- 235000013736 caramel Nutrition 0.000 claims description 9
- 229920002678 cellulose Polymers 0.000 claims description 9
- 239000001913 cellulose Substances 0.000 claims description 9
- 235000019359 magnesium stearate Nutrition 0.000 claims description 9
- 239000004408 titanium dioxide Substances 0.000 claims description 9
- 244000269722 Thea sinensis Species 0.000 claims description 8
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 8
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 8
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 8
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 8
- 239000000377 silicon dioxide Substances 0.000 claims description 8
- 235000012239 silicon dioxide Nutrition 0.000 claims description 8
- 210000002442 prefrontal cortex Anatomy 0.000 claims description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 3
- 239000000796 flavoring agent Substances 0.000 claims description 3
- 235000019634 flavors Nutrition 0.000 claims description 3
- 229920002230 Pectic acid Polymers 0.000 claims description 2
- 239000000783 alginic acid Substances 0.000 claims description 2
- 235000010443 alginic acid Nutrition 0.000 claims description 2
- 229920000615 alginic acid Polymers 0.000 claims description 2
- 229960001126 alginic acid Drugs 0.000 claims description 2
- 150000004781 alginic acids Chemical class 0.000 claims description 2
- 235000014171 carbonated beverage Nutrition 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
- 239000011707 mineral Substances 0.000 claims description 2
- 235000010755 mineral Nutrition 0.000 claims description 2
- 239000003002 pH adjusting agent Substances 0.000 claims description 2
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 claims description 2
- 239000010318 polygalacturonic acid Substances 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 239000000084 colloidal system Substances 0.000 claims 1
- 150000007524 organic acids Chemical class 0.000 claims 1
- 235000005985 organic acids Nutrition 0.000 claims 1
- 230000001681 protective effect Effects 0.000 claims 1
- 239000002562 thickening agent Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 11
- 238000000034 method Methods 0.000 abstract description 8
- 230000002360 prefrontal effect Effects 0.000 abstract description 5
- 230000001747 exhibiting effect Effects 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 19
- 210000004556 brain Anatomy 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 7
- 230000003340 mental effect Effects 0.000 description 7
- 230000007177 brain activity Effects 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 230000001936 parietal effect Effects 0.000 description 4
- WMAITHDYVBQITD-UHFFFAOYSA-N thunberginol c Chemical compound C1=CC(O)=CC=C1C1OC(=O)C2=C(O)C=C(O)C=C2C1 WMAITHDYVBQITD-UHFFFAOYSA-N 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 235000021329 brown rice Nutrition 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 238000007405 data analysis Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000001161 mammalian embryo Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 210000004761 scalp Anatomy 0.000 description 3
- 230000003595 spectral effect Effects 0.000 description 3
- 230000002123 temporal effect Effects 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- PBILBHLAPJTJOT-CQSZACIVSA-N Phyllodulcin Chemical compound C1=C(O)C(OC)=CC=C1[C@@H]1OC(=O)C2=C(O)C=CC=C2C1 PBILBHLAPJTJOT-CQSZACIVSA-N 0.000 description 2
- 102100021709 Rho guanine nucleotide exchange factor 4 Human genes 0.000 description 2
- 101710128386 Rho guanine nucleotide exchange factor 4 Proteins 0.000 description 2
- 229930003451 Vitamin B1 Natural products 0.000 description 2
- 230000037007 arousal Effects 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 210000003710 cerebral cortex Anatomy 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 2
- 229940107187 fructooligosaccharide Drugs 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000010365 information processing Effects 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 210000003478 temporal lobe Anatomy 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 235000010374 vitamin B1 Nutrition 0.000 description 2
- 239000011691 vitamin B1 Substances 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- PBILBHLAPJTJOT-UHFFFAOYSA-N 3S-phyllodulcin Natural products C1=C(O)C(OC)=CC=C1C1OC(=O)C2=C(O)C=CC=C2C1 PBILBHLAPJTJOT-UHFFFAOYSA-N 0.000 description 1
- 240000001810 Angelica gigas Species 0.000 description 1
- 235000018865 Angelica gigas Nutrition 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 240000006439 Aspergillus oryzae Species 0.000 description 1
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241001164374 Calyx Species 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 241001357959 Hydrangea serrata Species 0.000 description 1
- 241001091442 Hydrangeaceae Species 0.000 description 1
- DGKDFNDHPXVXHW-CYBMUJFWSA-N Hydrangenol Natural products C1=CC(O)=CC=C1[C@@H]1OC(=O)C2=C(O)C=CC=C2C1 DGKDFNDHPXVXHW-CYBMUJFWSA-N 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- RQDGXYMBVTZQNF-UHFFFAOYSA-N Thunberginol G Natural products C1=C(O)C(O)=CC=C1C1OC(=O)C2=C(O)C=CC=C2C1 RQDGXYMBVTZQNF-UHFFFAOYSA-N 0.000 description 1
- 229930003537 Vitamin B3 Natural products 0.000 description 1
- 229930003571 Vitamin B5 Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 235000020831 absolute fast Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 210000000624 ear auricle Anatomy 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 210000001652 frontal lobe Anatomy 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- UWXXIBUTKVUHTR-UHFFFAOYSA-N hydrangenic acid Natural products OC(=O)C1=C(O)C=CC=C1C=CC1=CC=C(O)C=C1 UWXXIBUTKVUHTR-UHFFFAOYSA-N 0.000 description 1
- DGKDFNDHPXVXHW-UHFFFAOYSA-N hydrangenol Chemical compound C1=CC(O)=CC=C1C1OC(=O)C2=C(O)C=CC=C2C1 DGKDFNDHPXVXHW-UHFFFAOYSA-N 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000001020 rhythmical effect Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- YEFOAORQXAOVJQ-RZFZLAGVSA-N schisandrol a Chemical compound C1[C@H](C)[C@@](C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-RZFZLAGVSA-N 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 229940035637 spectrum-4 Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229930187458 thunberginol Natural products 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019160 vitamin B3 Nutrition 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
- 235000009492 vitamin B5 Nutrition 0.000 description 1
- 239000011675 vitamin B5 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/31—Foods, ingredients or supplements having a functional effect on health having an effect on comfort perception and well-being
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/14—Extraction
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
본 발명은 긴장 및 집중 완화용 수국 추출 혼합 조성물, 상기 수국 추출 혼합 조성물을 포함하는 긴장 및 집중 완화용 건강기능식품, 긴장 및 집중 완화 효과를 지니는 수국 추출 혼합물의 제조방법 및 상기 방법으로 제조된 긴장 및 집중 완화 효과를 지니는 수국 추출 혼합물에 관한 것이다.The present invention relates to a hydrangea extract mixed composition for tense and concentration alleviation, a health functional food for stress and intensive alleviation comprising the hydrangea extract mixed composition, a method for producing a hydrangea extract mixture having a tension and concentration alleviating effect, And an extracting mixture of hydrangeas having a concentration alleviating effect.
뇌파는 인간 두뇌의 신경세포간의 활동에 의해서 발생한 율동적인 전기현상으로 대뇌피질 표면을 덮고 있는 조직, 두개골, 두피 등을 매개로 두피 위에 넓게 전해지며, 일반적으로 인간의 대뇌피질에서는 각성이나 수면상태에서도 항상 전위변동이 일어나고 있다. 대뇌피질의 신경세포로부터 발생된 미세한 전기활동은 두피 위에 전극을 부착하고, 두뇌에서 발생된 전기신호를 뇌파계에 입력시켜 시간에 따른 전위를 기록하여 측정할 수 있는데 이를 뇌전도(electroencephalogram, EEG)라고 한다. EEG is a rhythmic electrical phenomenon caused by the interaction between the nervous cells of the human brain, which is widely spread on the scalp through the tissues covering the surface of the cerebral cortex, the skull, and the scalp. Generally, in the human cerebral cortex, Potential fluctuations are always occurring. Electroencephalograms (EEGs) can be measured by attaching electrodes on the scalp and inputting electrical signals generated by the brain into the brain waves to record the potentials over time. do.
EEG는 시시각각으로 변화하는 뇌 활동의 변동을 시공간적으로 기록할 수 있고 비침습적, 연속적으로 간단하게 뇌의 기능을 측정할 수 있다는 장점이 있어서 뇌활동기록, 질병진단, 수면연구, 심리치료와 같은 인지과학, 의학, 약학 분야에서 폭넓게 활용되고 있다.EEG is able to record temporal and spatial changes of brain activity changing instantaneously, and it has the merit of being able to easily measure brain function non-invasively, consecutively, so that it can be used for brain activity record, diagnosis of disease, sleep study, Science, medicine, and medicine.
인간의 뇌파는 델타파(0.5~3Hz), 세타파(4~7Hz), 알파파(8~13Hz), 베타파(14~30Hz), 감마파(30Hz 이상)로 구분된다. 뇌파 중 알파파는 기본파로 표현되며 주파수는 8~13Hz이고, 진폭은 10~150V로 정상 성인의 각성, 안정, 폐안 상태에서 보인다. 알파파는 주파수 영역에 따라 slow 알파파(7~8Hz), mid 알파파(9~11Hz), fast 알파파(12~13Hz)로 구분된다.Human brain waves are divided into delta waves (0.5 to 3 Hz), theta waves (4 to 7 Hz), alpha waves (8 to 13 Hz), beta waves (14 to 30 Hz) and gamma waves (30 Hz and more). In EEG, alpha waves are expressed as fundamental waves, frequency is 8 ~ 13Hz, amplitude is 10 ~ 150V, and it is seen in normal adult arousal, stable, and closed state. Alpha waves are divided into slow and fast (7 ~ 8Hz), midal (9 ~ 11Hz) and fast (12 ~ 13Hz) depending on frequency.
Slow 알파파는 긴장이 풀려 있고, 잠들거나 휴식하면서 뇌가 집중하고 있는 상태에서 발생한다. 즉, 휴식에 대한 집중이지만 이것은 활동정지가 아니라 에너지를 보급하면서 언제든지 활동할 수 있는 상태를 유지하는 것이라 할 수 있다.Slow Alpha waves occur when the brain is concentrated while being relaxed, falling asleep, or resting. In other words, it is focused on rest, but it can be said that it is not stopping the activity, but maintaining the state that can act at any time while supplying energy.
Mid 알파파는 평상시의 사고 집중 상태로 긴장을 수반하지 않는 특징을 가지며, 명상, 창조적인 활동, 혹은 뇌에 새로운 정보나 지식을 효율적으로 주입할 때 나타나는 것으로 알려져 있다.The Mid Alpha is characterized by the usual concentration of accidents and does not involve tension, and is known to occur when meditation, creative activity, or efficient injection of new information or knowledge into the brain.
Fast 알파파는 극도로 긴장하여 무엇인가에 집중되어 있을 때 나타나는데 뇌는 반복 활동을 계속하는데 그 일에 집중하는 나머지 다른 것을 생각할 여유가 없으며 다른 신호나 자극에 반응하지 못한다. Fast Alpha Wave It appears when you are extremely nervous and focused on something. The brain keeps repeating, concentrating on it, can not afford to think of anything else, and does not respond to other signals or stimuli.
베타파는 14~30 Hz의 속파(fast wave)로, 5~10V의 낮은 진폭을 가지며, 일반적인 작업을 하거나 의식적인 행동을 할 때 나타나며 정보처리와 같은 정신활동이 있을 때 활성화된다.Beta waves are fast waves of 14 to 30 Hz, have low amplitudes of 5 to 10 V, appear when doing normal work or conscious actions, and are activated when there is mental activity such as information processing.
주파수 영역에 따라 slow 베타파(12-15Hz), mid 베타파(15-20Hz), high 베타파(20-30Hz)로 구분된다. Slow 베타파는 SMR(sensory motor rhythm)파라고도 하며 신체의 움직임이 없는 운동감각 피질의 활동을 최소화한 상태에서 주의를 기울이는 비교적 단순한 과제를 수행할 때 나타난다.It is divided into slow beta waves (12-15Hz), mid beta waves (15-20Hz) and high beta waves (20-30Hz) depending on the frequency domain. The Slow beta wave appears when performing a relatively simple task of paying attention while minimizing the activity of the motor sensory cortex, which is a sensory motor rhythm (SMR) paradigm.
Mid 베타파는 계산이나 암산과 같이 특정한 주제에 집중하면서 비교적 정신부하가 높은 사고활동을 수행할 때 나타난다. High 베타파는 비교적 복잡한 추론이나 정신부하가 높은 편인 복잡한 정보처리 활동을 수행하거나 혹은 정서적인 긴장, 불안, 흥분상태에서 우세해진다. 적당한 긴장 속에 일상 행동을 하고 있을 때 주로 베타파가 발생하여 일을 효과적으로 처리하지만, 스트레스가 심하여 지나친 긴장으로 흥분하게 되면 high 베타파가 발생한다.Mid Beta waves appear when you perform a relatively mental stressful activity while focusing on a specific topic, such as calculations or mental arithmetic. High Beta waves perform relatively complicated reasoning or complex information processing activities with high mental load, or become predominant in emotional tension, anxiety, and excitement. When you are in normal tension with proper tension, you usually get a beta wave, which works effectively, but when you are stressed and over-excited by tension, you get high beta waves.
수국(학명 Hydrangea macrophylla var. thunbergii)은 쌍떡잎식물 장미목 범의귀과의 낙엽관목으로 줄기는 높이 70 cm 정도로서 잎에 단맛이 있다. 꽃은 초여름에 피며 처음에는 푸른색이나 나중에는 홍색이 되며 중심부는 양성화이다. 주변부는 꽃받침이 변한 장식화로 둘러져 있다. 우리나라에서 일교차가 큰 해발 700 m의 강원도 강릉 고산지대에서 많이 자라며 경상남도 지역에서도 많이 재배된다. 신선한 잎에는 필로둘신(phyllodulcin)이 8-베타-글루코사이드의 형태로 들어 있어 단맛이 없으나 건조과정에서 효소 작용으로 분해되어 단맛을 내는 것으로 보고되어 있다. 필로둘신은 부드러운 단맛과 은은한 박하향이 어우러진 것이 특징이다.Hydrangea (Scientific name Hydrangea macrophylla var. Thunbergii) is a deciduous shrub of a dicotyledonous roe-mallow. Its stem is about 70 cm high and has sweetness on leaves. Flowers bloom in early summer, initially blue, then red, and the center is bisexual. The periphery is surrounded by ornaments with calyx. It grows much in Gangneung alpine region of Gangwon-do, 700m above sea level, and it is cultivated in Gyeongsangnam-do region. Fresh leaves contain phyllodulcin in the form of 8-beta-glucoside, which is not sweet but has been reported to be decomposed by enzymatic action in the drying process to produce a sweet taste. Pillow two gins are characterized by a soft sweetness and a soft peppermint.
수국에 함유된 히드란그산(hydrangenic acid), 툰베르기놀(thunberginol), 히드란게놀 4'-O-글루코시드(hydrangenol 4'-O-glucoside)는 구강세균에 대한 항균성과 항알러지성, 항당뇨성에 효과가 있는 것으로 알려져 있으며 수국은 식품의약품안전처의 식품원재료에 등재된 식물로 잎을 식용으로 사용가능하므로 특별한 독성시험 없이 사용이 가능한 안전한 식품원료이기에 스트레스로 인한 긴장 완화에 도움이 되는 기능성을 가지고 있다.Hydrangenic acid, thunberginol and hydrangenol 4'-O-glucoside in hydrangea are antimicrobial and anti-allergic to oral bacteria, It is known that it is effective for diabetic effect. Hydrone is a plant listed in food raw material of food and drug safety department. Because leaf can be used for food, it is safe food raw material that can be used without special toxicity test. Lt; / RTI >
한국등록특허 제1492074호에는 수국 추출물을 유효성분으로 함유하는 피부 미백용 조성물이 개시되어 있고, 한국등록특허 제1719162호에는 수국 추출물을 함유하는 알코올성 신경정신질환 예방 및 치료용 조성물이 개시되어 있으나, 본 발명의 긴장 및 집중 완화용 수국 추출 혼합 조성물과는 상이하다.Korean Patent No. 1492074 discloses a composition for skin whitening comprising an extract of hydrangea as an active ingredient and Korean Patent No. 1719162 discloses a composition for the prevention and treatment of alcoholic psychiatric disorders containing hydrangea extract, And is different from the hydroentangling mixed composition for relaxation and concentration alleviation of the present invention.
본 발명은 상기와 같은 요구에 의해 도출된 것으로서, 본 발명자들은 수국 추출 혼합 조성물을 이용하여 뇌파 변화를 분석한 결과, 본 발명의 수국 추출 혼합 조성물은 좌측 전전두엽에서 RHB(Relative High Beta Power Spectrum)의 감소를 유도하는 것을 확인함으로써, 본 발명을 완성하였다.As a result of analyzing EEG changes using the hydrangea extract compound composition, the inventors of the present invention found that the hydrangea extract mixed composition of the present invention can be applied to the left prefrontal cortex of RHB (Relative High Beta Power Spectrum) , Thereby completing the present invention.
상기 과제를 해결하기 위해, 본 발명은 수국(Hydrangea macrophylla) 추출 분말, 결정 셀룰로오스, 유당, 스테아린산마그네슘, 이산화규소, 히드록시프로필메틸 셀룰로오스, 카라멜 색소, 이산화티타늄 및 글리세린을 혼합한 혼합물을 유효성분으로 함유하는 긴장 및 집중 완화용 수국 추출 혼합 조성물을 제공한다.In order to solve the above-described problems, the present invention provides a pharmaceutical composition comprising as an active ingredient a mixture of Hydrangea macrophylla extract powder, crystalline cellulose, lactose, magnesium stearate, silicon dioxide, hydroxypropyl methylcellulose, caramel colorant, titanium dioxide and glycerin The present invention provides a hydrangea extract blending composition for relaxation and concentration alleviation which comprises
또한, 본 발명은 상기 수국 추출 혼합 조성물을 포함하는 긴장 및 집중 완화용 건강기능식품을 제공한다.In addition, the present invention provides a health functional food for stress and concentration alleviation comprising the hydrated extractive mixed composition.
또한, 본 발명은 (a) 수국차에 주정을 첨가하여 출한 후 여과 및 농축하고 건조하여 수국(Hydrangea macrophylla) 추출 분말을 준비하는 단계; 및 (b) 수국 추출 혼합물 총 중량 기준으로, 상기 (a)단계의 준비한 수국 추출 분말과 결정 셀룰로오스, 유당, 스테아린산마그네슘, 이산화규소, 히드록시프로필메틸 셀룰로오스, 카라멜 색소, 이산화티타늄 및 글리세린을 혼합하는 단계를 포함하는 긴장 및 집중 완화 효과를 지니는 수국 추출 혼합물의 제조방법을 제공한다.The present invention also relates to a method for preparing a hydrangea macrophylla extract, comprising the steps of: (a) adding a spirit to a hydrangea tea extract, filtering, concentrating and drying the hydrangea extract to prepare Hydrangea macrophylla extract powder; And (b) mixing the hydrated extract powder prepared in the step (a) with crystalline cellulose, lactose, magnesium stearate, silicon dioxide, hydroxypropylmethyl cellulose, caramel colorant, titanium dioxide and glycerin Wherein the hydrangea extract mixture has a stress and concentration alleviating effect.
또한, 본 발명은 상기 방법으로 제조된 긴장 및 집중 완화 효과를 지니는 수국 추출 혼합물을 제공한다.In addition, the present invention provides a hydrangea extract mixture having the stress and concentration alleviating effect produced by the above method.
본 발명의 수국 추출 혼합 조성물은 수국 추출 혼합물 섭취를 통해, 좌측 전전두엽에서 RHB(Relative High Beta Power Spectrum)의 감소를 유도하여 긴장 및 집중 완화 효과를 얻을 수 있다. 또한, 본 발명의 수국 추출 혼합 조성물을 식품에 첨가하여 긴장 및 집중 완화를 유도하는 건강기능식품의 개발에 사용될 수 있다.The hydronephritic extraction mixed composition of the present invention can induce reduction of Relative High Beta Power Spectrum (RHB) in the left prefrontal cortex through ingestion of hydrangea extract mixture to obtain a tension and concentration relaxation effect. In addition, the hydrangea extract mixed composition of the present invention can be added to food to be used for the development of a health functional food which induces relaxation and concentration relaxation.
도 1은 수국 추출 분말의 툰베르기놀(thunberginol) C 함량을 HPLC로 분석한 결과를 보여준다.
도 2는 뇌파 측정을 위해 인간의 두뇌에 전극을 붙이는 부위를 제시한 10-20 국제표준 전극부착법을 보여주는 사진이다.
도 3은 피험자의 두뇌에 EGG용 모자를 씌우고 뇌파를 측정하는 모습을 보여주는 사진이다.FIG. 1 shows the results of HPLC analysis of the content of thunberginol C in the hydrangea extract powder.
FIG. 2 is a photograph showing a 10-20 international standard electrode attaching method showing a region where an electrode is attached to a human brain for EEG measurement.
FIG. 3 is a photograph showing an EGG cap placed on a subject's brain and measuring brain waves.
본 발명의 목적을 달성하기 위하여, 본 발명은 수국(Hydrangea macrophylla) 추출 분말, 결정 셀룰로오스, 유당, 스테아린산마그네슘, 이산화규소, 히드록시프로필메틸 셀룰로오스, 카라멜 색소, 이산화티타늄 및 글리세린을 혼합한 혼합물을 유효성분으로 함유하는 긴장 및 집중 완화용 수국 추출 혼합 조성물을 제공한다.In order to achieve the object of the present invention, the present invention provides a method for producing a mixture of hydrangea macrophylla extract powder, crystalline cellulose, lactose, magnesium stearate, silicon dioxide, hydroxypropyl methylcellulose, caramel colorant, titanium dioxide and glycerin As a component of the hydrangea extract mixture composition for relaxation and concentration relaxation.
본 발명의 수국 추출 혼합 조성물에서, 상기 혼합물은 구체적으로는 수국차에 60~70%(v/v) 주정을 8~12배(v/w) 첨가한 후 50~70℃에서 1~3시간씩 1~3회 추출한 후 여과 및 농축하고 건조한 수국(Hydrangea macrophylla) 추출 분말 48~52 중량%, 결정 셀룰로오스 40~45 중량%, 유당 1.8~2.2 중량%, 스테아린산마그네슘 0.6~0.9 중량%, 이산화규소 0.6~0.9 중량%, 히드록시프로필메틸 셀룰로오스 1.3~1.7 중량%, 카라멜 색소 1.3~1.7 중량%, 이산화티타늄 0.5~0.7 중량% 및 글리세린 0.1~0.3 중량%를 혼합한 혼합물일 수 있으며, 더욱 구체적으로는 수국차에 65%(v/v) 주정을 10배(v/w) 첨가한 후 60℃에서 2시간씩 2회 추출한 후 여과 및 농축하고 건조한 수국(Hydrangea macrophylla) 추출 분말 50 중량%, 결정 셀룰로오스 42.7 중량%, 유당 2 중량%, 스테아린산마그네슘 0.75 중량%, 이산화규소 0.75 중량%, 히드록시프로필메틸 셀룰로오스 1.5 중량%, 카라멜 색소 1.5 중량%, 이산화티타늄 0.6 중량% 및 글리세린 0.2 중량%를 혼합한 혼합물일 수 있다.In the hydrangea extract mixing composition of the present invention, the mixture is added specifically to the hydrangea tea at a rate of 8 to 12 times (v / w) at 60 to 70% (v / v) , 48 to 52% by weight of hydrangea macrophylla extract powder, 1 to 3 times of filtration, concentrated and dried, 40 to 45% by weight of crystalline cellulose, 1.8 to 2.2% by weight of lactose, 0.6 to 0.9% by weight of magnesium stearate, The mixture may be a mixture of 0.6 to 0.9 wt% of hydroxypropylmethylcellulose, 1.3 to 1.7 wt% of hydroxypropylmethylcellulose, 1.3 to 1.7 wt% of caramel colorant, 0.5 to 0.7 wt% of titanium dioxide and 0.1 to 0.3 wt% of glycerin, (V / v) of 65% (v / v) alcohol was added to the hydrangea tea, and the mixture was extracted twice at 60 ° C for 2 hours, then filtered and concentrated to obtain 50 wt.% Hydrangea macrophylla extract powder, 42.7% by weight of cellulose, 2% by weight of lactose, 0.75% by weight of magnesium stearate, 0.75% by weight of silicon dioxide, 1.5% by weight of ropil methyl cellulose, 1.5% by weight of caramel colorant, 0.6% by weight of titanium dioxide and 0.2% by weight of glycerin.
본 발명의 수국 추출 혼합 조성물은 좌측 전전두엽에서 RHB(Relative High Beta Power Spectrum)의 감소를 유도하여 긴장 및 집중 완화 효과를 나타내는 것을 특징으로 한다.The hydronephritic mixed composition of the present invention is characterized by exhibiting a relaxation and concentration-reducing effect by inducing a reduction of RHB (Relative High Beta Power Spectrum) in the left prefrontal cortex.
RHB는 전체에서 high beta파의 비율을 의미하는 것으로, beta파는 일반적인 작업을 하거나 의식적인 행동을 할 때 나타나며 정신활동이 있을 때 활성화되므로, beta파의 감소는 두뇌 상태를 안정화시키고 이완시켜 심리적으로 편안함을 증가시킨다. RHB refers to the proportion of high beta waves in the whole, where beta waves appear when doing normal work or conscious behavior and are activated when there is mental activity, so the reduction of beta waves stabilizes and relaxes the brain state, .
또한, 본 발명은 수국 추출 혼합 조성물을 포함하는 긴장 및 집중 완화용 건강기능식품을 제공한다.The present invention also provides a health functional food for stress and concentration alleviation comprising the hydrated extractive mixed composition.
상기 건강기능식품은 여러 가지 영양제, 비타민, 광물(전해질), 합성 및 천연 풍미제, 착색제 및 증진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 그 밖에 천연 과일 주스 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. The health functional food may contain various nutrients, vitamins, minerals (electrolytes), synthetic and natural flavors, colorants and enhancers (cheese, chocolate etc.), pectic acid and its salts, alginic acid and its salts, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated drinks, and the like. It may also contain flesh for the production of natural fruit juices and vegetable drinks. These components may be used independently or in combination.
본 발명의 건강기능식품은 여러가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상기 천연 탄수화물은 포도당, 과당과 같은 모노사카라이드, 말토스, 슈크로스와 같은 디사카라이드, 및 덱스트린, 사이클로덱스트린과 같은 폴리사카라이드, 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 감미제로서는 타우마틴, 스테비아 추출물과 같은 천연 감미제나, 사카린, 아스파르탐과 같은 합성 감미제 등을 사용할 수 있다.The health functional food of the present invention may contain various flavors or natural carbohydrates as an additional ingredient. The natural carbohydrates are sugar saccharides such as monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, xylitol, sorbitol and erythritol. Examples of sweeteners include natural sweeteners such as tau martin and stevia extract, synthetic sweeteners such as saccharin and aspartame, and the like.
본 발명은 또한,The present invention also relates to
(a) 수국차에 60~70%(v/v) 주정을 8~12배(v/w) 첨가한 후 50~70℃에서 1~3시간씩 1~3회 추출한 후 여과 및 농축하고 건조하여 수국(Hydrangea macrophylla) 추출 분말을 준비하는 단계; 및(a) 60 to 70% (v / v) alcohol was added to the water tea at 8 to 12 times (v / w) and then extracted 1 to 3 times at 50 to 70 ° C for 1 to 3 hours. Preparing Hydrangea macrophylla extract powder; And
(b) 수국 추출 혼합물 총 중량 기준으로, 상기 (a)단계의 준비한 수국 추출 분말 48~52 중량%와 결정 셀룰로오스 40~45 중량%, 유당 1.8~2.2 중량%, 스테아린산마그네슘 0.6~0.9 중량%, 이산화규소 0.6~0.9 중량%, 히드록시프로필메틸 셀룰로오스 1.3~1.7 중량%, 카라멜 색소 1.3~1.7 중량%, 이산화티타늄 0.5~0.7 중량% 및 글리세린 0.1~0.3 중량%를 혼합하는 단계를 포함하는 긴장 및 집중 완화 효과를 지니는 수국 추출 혼합물의 제조방법을 제공한다.(b) 48 to 52% by weight of hydrangea extract powder prepared in the step (a), 40 to 45% by weight of crystalline cellulose, 1.8 to 2.2% by weight of lactose, 0.6 to 0.9% by weight of magnesium stearate, Comprising mixing 0.6 to 0.9% by weight of silicon dioxide, 1.3 to 1.7% by weight of hydroxypropylmethylcellulose, 1.3 to 1.7% by weight of caramel dyes, 0.5 to 0.7% by weight of titanium dioxide and 0.1 to 0.3% by weight of glycerin, Provided is a method for producing a hydrangea extract mixture having a concentrated relaxation effect.
본 발명의 긴장 및 집중 완화 효과를 지니는 수국 추출 혼합물의 제조방법은, 보다 구체적으로는The method for producing the hydrangea extract mixture of the present invention having the effect of tautness and concentration alleviation, more specifically,
(a) 수국차에 65%(v/v) 주정을 10배(v/w) 첨가한 후 60℃에서 2시간씩 2회 추출한 후 여과 및 농축하고 건조하여 수국(Hydrangea macrophylla) 추출 분말을 준비하는 단계; 및(a) 65% to hydrangea tea (v / v) to 10 times ethanol (v / w) was added and then extracted twice with 60 ℃ for 2 hours, filtered and concentrated and dried hydrangea (Hydrangea macrophylla) preparing an extract powder ; And
(b) 수국 추출 혼합물 총 중량 기준으로, 상기 (a)단계의 준비한 수국 추출 분말 50 중량%와 결정 셀룰로오스 42.7 중량%, 유당 2 중량%, 스테아린산마그네슘 0.75 중량%, 이산화규소 0.75 중량%, 히드록시프로필메틸 셀룰로오스 1.5 중량%, 카라멜 색소 1.5 중량%, 이산화티타늄 0.6 중량% 및 글리세린 0.2 중량%를 혼합하는 단계를 포함할 수 있다.(b) extracting hydrangea powder comprising 50% by weight of the hydrated extract powder prepared in the step (a), 42.7% by weight of crystalline cellulose, 2% by weight lactose, 0.75% by weight magnesium stearate, 0.75% by weight silicon dioxide, 1.5% by weight of propyl methylcellulose, 1.5% by weight of caramel colorant, 0.6% by weight of titanium dioxide and 0.2% by weight of glycerin.
본 발명은 또한, 상기 방법으로 제조된 긴장 및 집중 완화 효과를 지니는 수국 추출 혼합물을 제공한다.
The present invention also provides a hydrangea extract mixture having the tautness and concentration alleviating effect produced by the above method.
이하, 본 발명을 실시예에 의해 상세히 설명한다. 단, 하기 실시예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시예에 한정되는 것은 아니다.
Hereinafter, the present invention will be described in detail with reference to examples. However, the following examples are illustrative of the present invention, and the present invention is not limited to the following examples.
제조예Manufacturing example 1. 수국 추출 분말 제조 1. Manufacture of hydrangea extract powder
7월과 8월에 걸쳐 채취한 수국(Hydrangea macrophylla)의 잎을 햇빛에 잘 건조시키고, 수국 잎 각 부분의 수분함량을 균일하게 하고 세포조직을 적당히 파괴하여 포함된 성분이 추출 시 잘 우러나도록 수국의 녹색 잎이 암갈색이 될 때까지 유념기를 이용하여 비벼 말린 형태로 만드는 공정으로서 유념을 실시하였다. 상기 유념한 수국 잎을 밀폐 용기에 넣어 밀봉한 후, 37℃에서 12시간 동안 숙성한 후 햇볕에 완전히 건조하여 수국차를 제조하였다. Hydrangea macrophylla leaves were dried in the sunlight in July and August, the water content of each part of hydrangea leaves was uniformed, the cell tissue was properly destroyed, and hydrangea Was used as a process to make the green leaf in a dark brown color by using an observing machine. The noted hydrangea leaves were sealed in a sealed container, aged at 37 캜 for 12 hours, and dried thoroughly in the sun to prepare hydrangea tea.
상기 제조한 수국차 1 kg을 분쇄하고, 여기에 65% 주정 10 L를 넣고 60℃에서 2시간씩 2회 추출한 후 여과지(세공 0.7 마이크로미터)를 이용하여 감압 여과하였다. 상기 여과한 추출물을 50℃에서 16~18 기압 조건에서 농축시켜 농축액을 제조하였다. 상기 제조한 농축액에 농축액의 고형분 함량과 1:1 중량비율로 덱스트린을 녹인 후 분무 건조하였다.1 kg of the hydrangea tea prepared above was pulverized, 10 L of 65% ethanol was added thereto, and the mixture was extracted twice at 60 ° C for 2 hours, and then filtered under reduced pressure using a filter paper (pore 0.7 micrometer). The filtrate was concentrated at 50 to < RTI ID = 0.0 > 18 < / RTI > Dextrin was dissolved in the concentrate in a 1: 1 weight ratio with the solid content of the concentrate, followed by spray drying.
상기 제조한 수국 추출 분말을 메탄올에 녹여 HPLC로 분석하였을 때 유효성분인 툰베르기놀(thunberginol) C는 0.02% 이상인 것을 확인하였다(도 1).
When the hydronephric extract powder prepared above was dissolved in methanol and analyzed by HPLC, it was confirmed that the active ingredient, thunberginol C, was 0.02% or more (Fig. 1).
제조예Manufacturing example 2. 수국 추출 혼합물 제조 2. Manufacture of hydrangea extract mixture
제조예 1에서 얻은 수국 추출 분말 50 중량%와 결정 셀룰로오스 42.7 중량%, 유당 2 중량%, 스테아린산마그네슘 0.75 중량%, 이산화규소 0.75 중량%, 히드록시프로필메틸 셀룰로오스 1.5 중량%, 카라멜 색소 1.5 중량%, 이산화티타늄 0.6 중량%, 글리세린 0.2 중량%를 혼합하여 수국 추출 혼합물을 제조하였다.
A mixture of 50% by weight of the hydrated extract powder obtained in Preparation Example 1, 42.7% by weight of crystalline cellulose, 2% by weight lactose, 0.75% by weight magnesium stearate, 0.75% by weight silicon dioxide, 1.5% by weight hydroxypropylmethylcellulose, 1.5% by weight caramel colorant, 0.6% by weight of titanium dioxide and 0.2% by weight of glycerin were mixed to prepare a hydrangea extract mixture.
비교예Comparative Example 1. 수국 추출 혼합물 1. Hydrone extract mixture
(a) 현미배아 및 프락토올리고당을 94:5 중량비율로 혼합한 후 100℃에서 10~30분 동안 살균한 혼합물을 36℃ 이하로 냉각한 후, 상기 냉각한 혼합물에 황국균(Aspergillus oryzae)을 99:1 중량비율로 혼합한 후 멸균수를 첨가하여 36℃ 온도 및 상대습도 60%의 조건으로 48~96시간 동안 배양하였다. 상기 배양한 배양물을 45℃에서 6~10시간 동안 건조하여 수분함량이 8%(v/w) 이하가 되도록 건조하여 현미배아효소를 제조하였다.(a) a mixture of a brown rice embryo and a fructooligosaccharide in a weight ratio of 94: 5 and then sterilized at 100 ° C for 10 to 30 minutes was cooled to 36 ° C or lower, and then cooled to an Aspergillus oryzae were mixed in a weight ratio of 99: 1, sterilized water was added, and the mixture was incubated at 36 ° C. and 60% relative humidity for 48 to 96 hours. The cultured cultures were dried at 45 ° C for 6 to 10 hours, and dried to a moisture content of 8% (v / w) or less to prepare brown rice embryo enzymes.
(b) 수국 잎 25 중량%, 당귀 20 중량%, 상기 (a)단계의 제조한 현미배아효소 20 중량%, 황금 20 중량%, 오미자 10 중량% 및 하수오 5 중량%를 혼합하여 수국 혼합물을 준비하였다.(b) hydrangea blend was prepared by mixing 25% by weight of hydrangea leaves, 20% by weight of Angelica gigas, 20% by weight of the brown rice embryo enzyme prepared in step (a), 20% by weight of gold, 10% by weight of omija and 5% Respectively.
(c) 상기 (b)단계의 수국 혼합물을 추출포에 담고 물을 혼합물 중량 대비 10배량 첨가한 후 100℃ 온도 및 1~2 kgf/cm2의 압력에서 12시간 동안 추출하였다. 상기 추출한 추출물을 5 ㎛ 필터로 여과한 여과액을 감압농축기를 이용하여 60℃에서 고형분 함량이 20%(w/v)가 되도록 농축하였다. 상기 농축한 농축액을 분무건조기(열풍온도 180℃, 배풍온도 103℃, 디스크 속도 10,000 rpm)를 이용하여 분말화하여 수국추출분말을 제조하였다.(c) The hydrangea mixture of step (b) was added to the extract and water was added 10 times by weight of the mixture, and the mixture was extracted at a temperature of 100 ° C. and a pressure of 1 to 2 kgf / cm 2 for 12 hours. The extracted extract was filtered with a 5 탆 filter, and the filtrate was concentrated to a solid content of 20% (w / v) at 60 캜 by using a vacuum concentrator. The concentrated concentrate was pulverized using a spray drier (hot air temperature 180 占 폚, air temperature 103 占 폚, disk speed 10,000 rpm) to prepare hydrangea extract powder.
(d) 상기 (c)단계의 제조한 수국 추출 분말 35 중량%, 프락토올리고당 30.96 중량%, 말토덱스트린 25 중량%, 이노시톨 5 중량%, 타우린 2 중량%, 수국향 1 중량%, 효소처리스테비아 1 중량%, 비타민 B1 0.01 중량%, 비타민 B3 0.01 중량%, 비타민 B5 0.01 중량% 및 비타민 B6 0.01 중량%를 혼합하였다.
(d) the hydrolyzate extract powder prepared in the step (c), 35 wt% of fructooligosaccharide, 30 wt% of maltodextrin, 5 wt% of inositol, 2 wt% of taurine, 1% by weight of vitamin B1, 0.01% by weight of vitamin B1, 0.01% by weight of vitamin B3, 0.01% by weight of vitamin B5 and 0.01% by weight of vitamin B6.
비교예Comparative Example 2. 2. 산수국Mountain landscape 추출 혼합물 Extraction mixture
상기 제조예 2의 방법으로 추출 혼합물을 제조하되, 수국(Hydrangea macrophylla)을 사용하지 않고, 산수국(Hydrangea serrata)을 사용하여 산수국 추출 혼합물을 제조하였다.
The extract mixture was prepared by the method of Preparation Example 2, except that hydrangea macrophylla was not used, and Hydrangea serrata was used to prepare an extract of a mountain water soup.
실시예Example 1. 수국 추출 혼합물이 뇌파에 미치는 영향 분석 1. Effects of extractive hydration mixture on EEG
제조예 2의 수국 추출 혼합물의 섭취가 인간의 뇌 활동에 어떠한 영향을 주었는지를 알고자 뇌파를 측정하였다. 뇌파 측정은 최대한 잡음이 혼입되지 않은 온도 23℃, 습도 50%가 유지되는 32.4 m2 크기의 실험실에서 남, 녀 각각 10명 총 20명의 피험자를 대상으로 수행하였다. 뇌파측정을 위해 사용한 뇌파측정기는 QEEG-64FX 시스템(LAXTHA Inc. 한국)이었으며, 피험자의 뇌파신호 측정은 LAXTHA사의 데이터 수집 장비 및 분석 프로그램(Telescan)을 이용하였다. 피험자들에게 10~20 국제표준전극 부착법을 이용하여 좌측과 우측 전전두엽(Fp1, Fp2, Fpz, Af3, Af4, Afz), 좌측과 우측 전두엽(F3, F4, F7, F8, Fz, Fc1, Fc2, Fc5, Fc6), 좌측과 우측 측두엽(T3, T4, T7, T8, Cp5, Cp6), 좌측과 우측 두정엽(P3, P4, P7, P8, Cp1, Cp2, Cz, Pz), 좌측과 우측 후두엽(O1, O2, Oz) 부분에 부착하고 오른쪽과 왼쪽 귓불에도 각각 그라운드 및 레퍼런스 전극을 부착하였다(도 2 및 3). 피험자가 눈을 감은 상태에서 맹물 시음(무자극)과 수국 추출 혼합물 섭취(유자극)로 하여 각각 45초씩 측정하였다.The brain waves were measured in order to know how the intake of the hydrangea extract mixture of Preparation Example 2 affected human brain activity. EEG measurements were performed on a total of 20 subjects, 10 of each male and female, in a laboratory of 32.4 m 2 in which the noise was not mixed and the temperature was maintained at 23 ° C and 50% humidity. The EEG used for the EEG was a QEEG-64FX system (LAXTHA Inc. Korea). EEG signals were measured using LAXTHA's data collection equipment and analysis program (Telescan). The left and right prefrontal cords (Fp1, Fp2, Fpz, Af3, Af4, Afz), left and right frontal lobes (F3, F4, F7, F8, Fz, Fc1, Fc2, Left and right temporal lobes (P3, P4, P7, P8, Cp1, Cp2, Cz, Pz), left and right temporal lobes (T3, T4, T7, T8, Cp5, Cp6) O1, O2, and Oz), and ground and reference electrodes were attached to the right and left earlobes, respectively (FIGS. 2 and 3). Subjects were examined for 45 seconds with eyes closed (no irritation) and with hydrangea extract (dietary stimulation).
수국 추출 혼합물에 대한 뇌파측정을 통해 얻어진 데이터 처리는 피험자의 뇌파신호 중 대표적인 30초간의 뇌파신호만을 추출하여 뇌파일괄처리 프로그램(batch processing)으로 수행한 후, 통계분석 소프트웨어 프로그램인 SPSS(SPSS 23.0 version)를 이용하여 대응표본 T 검정을 수행하였다.The data processing obtained by the EEG extraction of the hydronephritic extract mixture was performed by extracting only a representative 30-second EEG signal among the EEG signals of the subject and performing an EEG batch processing. Then, the statistical analysis software program SPSS (SPSS 23.0 version ) Was used to perform a corresponding sample T test.
수국 추출 혼합물에 대한 데이터 분석을 위한 뇌파 지표의 종류는 표 1에, 그리고 각각의 뇌파 지표의 의미는 표 2에 나타내었다.Table 1 shows the types of EEG indices for data analysis of hydronephrine extract mixtures, and Table 2 shows the meanings of EEG indices.
본 실시예에서 수국 추출 혼합물에 대한 뇌파측정 결과, 25개의 뇌파분석 지표 중 RHB(Relative High Beta Power Spectrum) 지표에서만 통계적인 유의차가 있는 것을 나타났다(p<0.05). 나마지 24개의 파워 스펙트럼은 유의적인 차이가 나타나지 않았기 때문에 본 실시예에서는 기술하지 않았다.
In the present embodiment, EEG measurement results showed that there was a statistically significant difference only in RHB (Relative High Beta Power Spectrum) index among 25 EEG analysis indexes ( p <0.05). Since the power spectra of the twenty-four power amplifiers were not significantly different from each other, they were not described in this embodiment.
그 결과, 본 발명의 수국 추출 혼합물의 시음이 좌측 전전두엽의 Fp1 부위에서 RHB(relative high beta power spectrum)을 감소를 유도하여 긴장과 집중을 완화시키는 효과를 낸다는 것을 알 수 있었다(표 3).As a result, it was found that the tasting of the hydrangea extract mixture of the present invention resulted in reducing the relative high beta power spectrum (RHB) at the Fp1 site of the left prefrontal cortex, thereby relieving tension and concentration (Table 3).
실시예Example 2. 추출 혼합물의 2. Of the extraction mixture RHBRHB 파워 스펙트럼에 미치는 영향 Impact on Power Spectrum
제조예 1과 비교예들의 추출 혼합물의 섭취 후 RHB에 대한 변화를 관찰한 결과는 하기 표 4와 같다. 그 결과, 제조예 1의 수국 추출 혼합물은 Fp1 부위에서 RHB(Relative High Beta Power Spectrum) 지표를 감소하는 효과를 나타낸 반면(p<0.05), 비교예 1 및 비교예 2의 추출 혼합물은 모든 뇌 위치에서 RHB 지표에서는 영향을 주지 않음을 확인할 수 있었다.The results of observing changes in RHB after the ingestion of the extract mixture of Preparation Example 1 and Comparative Example are shown in Table 4 below. As a result, the hydrangea extract mixture of Preparation Example 1 showed an effect of reducing the Relative High Beta Power Spectrum (RHB) index at the Fp1 site ( p < 0.05), while the extract mixture of Comparative Example 1 and Comparative Example 2 showed all brain sites In the RHB index.
Fp1/Af3: 좌측 전전두엽(left prefrontal), Fp2/Af4: 우측 전전두엽(Right prefrontal), Fpz/Afz: 중앙 전전두엽(Central prefrontal), F3/F7/Fc1/Fc5: 좌측 전두엽(Left frontal), F4/F8/Fc2/Fc6: 우측 전두엽(Right frontal), Fz: 중앙 전두엽(Contral frontal), T3/T7/Cp5: 좌측 측두엽(Left tomporal), T4/T8/Cp6: 우측 측두엽(Right temporal), P3/P7/Cp1: 좌측 두정엽(Left parietal), P4/P8/Cp2: 우측 두정엽(Right parietal), Cz/Pz: 중앙 두정엽(Central parietal), O1: 좌측 후두엽(Left occipital), O2: 우측 후두엽(Right occipital), Oz: 중앙 후두엽(Central occipital)Fp1 / Af3: Left prefrontal, Fp2 / Af4: Right prefrontal, Fpz / Afz: Central prefrontal, F3 / F7 / Fc1 / Fc5: Left frontal, F4 / T3 / T7 / Cp5: Left temporal, T4 / T8 / Cp6: Right temporal, P3 / T6 / Fc6: Right frontal, Fz: Central frontal, P4 / Cp1: Left parietal, P4 / P8 / Cp2: Right parietal, Cz / Pz: Central parietal, O1: Left occipital, O2: Right occipital (Right parietal) occipital), Oz: central occipital (Central occipital)
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180151614A KR101997023B1 (en) | 2018-11-30 | 2018-11-30 | Hydrangea macrophylla extract mixed composition for relaxation and reducing concentration and uses thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180151614A KR101997023B1 (en) | 2018-11-30 | 2018-11-30 | Hydrangea macrophylla extract mixed composition for relaxation and reducing concentration and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
KR101997023B1 true KR101997023B1 (en) | 2019-07-05 |
Family
ID=67224978
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020180151614A KR101997023B1 (en) | 2018-11-30 | 2018-11-30 | Hydrangea macrophylla extract mixed composition for relaxation and reducing concentration and uses thereof |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101997023B1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102221353B1 (en) * | 2019-11-18 | 2021-03-02 | 대구한의대학교산학협력단 | Composition comprising the extract of Campsis grandiflora and Hydrangea macrophylla for preventing or treating neuro degenerative disease |
KR20210050187A (en) * | 2019-10-28 | 2021-05-07 | 제주대학교 산학협력단 | Composition comprising thunberginol C for preventing and treating of stress diseases |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20160081206A (en) * | 2014-12-31 | 2016-07-08 | (주)아모레퍼시픽 | Aromatic composition containing extract of hydrangea serrata for psychological relaxation |
KR20170078504A (en) * | 2015-12-28 | 2017-07-07 | 제주대학교 산학협력단 | Composition comprising extract of Hydrangeae Dulcis Folium for preventing and treating of stress diseases |
KR101847375B1 (en) * | 2017-08-28 | 2018-04-11 | 강원대학교산학협력단 | Dandelion mixed extract composition for improving brain comfort when tasting and uses thereof |
KR20180057515A (en) * | 2016-11-22 | 2018-05-30 | (주)백천바이오텍 | Method for producing Hydrangea macrophylla tea having attention and concentration strengthening effect |
-
2018
- 2018-11-30 KR KR1020180151614A patent/KR101997023B1/en active IP Right Grant
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20160081206A (en) * | 2014-12-31 | 2016-07-08 | (주)아모레퍼시픽 | Aromatic composition containing extract of hydrangea serrata for psychological relaxation |
KR20170078504A (en) * | 2015-12-28 | 2017-07-07 | 제주대학교 산학협력단 | Composition comprising extract of Hydrangeae Dulcis Folium for preventing and treating of stress diseases |
KR20180057515A (en) * | 2016-11-22 | 2018-05-30 | (주)백천바이오텍 | Method for producing Hydrangea macrophylla tea having attention and concentration strengthening effect |
KR101847375B1 (en) * | 2017-08-28 | 2018-04-11 | 강원대학교산학협력단 | Dandelion mixed extract composition for improving brain comfort when tasting and uses thereof |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210050187A (en) * | 2019-10-28 | 2021-05-07 | 제주대학교 산학협력단 | Composition comprising thunberginol C for preventing and treating of stress diseases |
KR102351324B1 (en) * | 2019-10-28 | 2022-01-14 | 제주대학교 산학협력단 | Composition comprising thunberginol C for preventing and treating of stress diseases |
KR102221353B1 (en) * | 2019-11-18 | 2021-03-02 | 대구한의대학교산학협력단 | Composition comprising the extract of Campsis grandiflora and Hydrangea macrophylla for preventing or treating neuro degenerative disease |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103549056B (en) | A kind of relieving alcoholism and protecting liver cold tea | |
CN112369492A (en) | Gel candy capable of calming heart, soothing nerves and improving sleep and preparation method thereof | |
KR101997023B1 (en) | Hydrangea macrophylla extract mixed composition for relaxation and reducing concentration and uses thereof | |
CN102860549A (en) | Functional beverage having functions of beautifying and detoxification and preparation method thereof | |
KR101922466B1 (en) | Method for producing Hydrangea macrophylla tea having attention and concentration strengthening effect | |
KR101847375B1 (en) | Dandelion mixed extract composition for improving brain comfort when tasting and uses thereof | |
CN113811320A (en) | Plant composition, preparation method and application thereof | |
CN106821856A (en) | A kind of seven black hair blackening cosmetic compositions and preparation method thereof | |
CN113559037B (en) | Cassia seed compound collagen liposome and application thereof | |
KR101533673B1 (en) | Perfume composition for expressing the fragrance of gardenia jasminoides Ellis for. Grandiflora Makino | |
KR101980599B1 (en) | Mixed fermentation solution composition of Orostachys japonica and pine needle for enhancing attention and concentration and uses thereof | |
KR20190052958A (en) | Aronia fermentation solution composition for relaxation and uses thereof | |
KR101654737B1 (en) | A composition having extracts of trifoliate orange for release of hangover and manufacturing method thereof | |
KR101855741B1 (en) | Mixed composition of β-carotene for relaxation and uses thereof | |
KR102342136B1 (en) | Jaw-line correction cosmetic mask pack | |
CN110772456B (en) | Miracle fruit leaf compound and application thereof in anti-melanin formation product | |
KR20140018699A (en) | Method for manufacturing hair growth promotion/hair loss prevention shampoo. | |
CN105995711A (en) | Fructus phyllanthi compound preparation and preparation method thereof | |
KR101877290B1 (en) | Aroma composition with grape flavor containing essential oil of Schisandra chinensis and Angelica gigas for enhancing concentration state and uses thereof | |
CN107375374B (en) | A kind of fermentation extraction method for the American ginseng extract that there is auxiliary to improve sleep effect | |
KR100512449B1 (en) | The method for manufacturing of tea | |
EP3881854A1 (en) | Composition comprising plant extract of genus fraxinus as active ingredient for preventing, alleviating, or treating sleep disorders | |
KR101997028B1 (en) | Mixed composition of lactic acid bacteria for enhancing awakening and uses thereof | |
KR20150129461A (en) | Sasa quelpaertensis nakai tea and manufacture method thereof | |
KR20210002221A (en) | Red ginseng products containing noni and the process for the preparation thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AMND | Amendment | ||
AMND | Amendment | ||
X701 | Decision to grant (after re-examination) | ||
GRNT | Written decision to grant |